Johnson & Johnson (JNJ) stock prices updated...
 

Johnson & Johnson stock price, JNJ

Johnson & Johnson stock chart:



Johnson & Johnson close price: 119.66

Stock price forecast:

DOWN TO -4.36%
Target: 114.44

Total forecasts: 90
Reached: 83 (92.22%)

Total Win: 161.59 (142.26%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90918492.31%163.661.58%827.00-10.62-1.28%153.041.47%
30312580.65%58.561.66%710.72-7.24-1.02%51.321.44%
1415960.00%19.271.12%710.72-7.24-1.02%12.030.69%
78225.00%2.440.26%710.72-7.24-1.02%-4.80-0.51%

Showing 1-10 of 480 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-02-21118.86114.40000-00-00
2017-02-20118.86113.980000-00-00
2017-02-19118.86116.290000-00-00
2017-02-18118.86116.260000-00-00
2017-02-17118.08116.210000-00-00
2017-02-16117.2116.650000-00-00
2017-02-15116.36117.642017-02-16
2017-02-14115.88117.042017-02-15
2017-02-13115.24116.662017-02-15
2017-02-12115.24116.82017-02-15

Johnson & Johnson latest news:


  • 01/26/2017 14:24:56

    Johnson & Johnson refills drug cabinet with $30 billion Actelion deal

    ALLSCHWIL, Switzerland (Reuters) - U.S. healthcare giant Johnson & Johnson will buy Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, the companies said on Thursday.

  • 01/26/2017 12:18:20

    Johnson & Johnson agrees $30bn deal for Actelion 

    Founder Jean-Paul Clozel to head up standalone spin-off research company

  • 01/26/2017 02:28:47

    Johnson & Johnson to buy Actelion for $30bn

    Swiss biotech group’s founder to head up standalone spin-off research company

  • 01/26/2017 01:52:18

    Johnson & Johnson to Acquire Actelion for $30 Billion

    The acquisition of the Swiss biotechnology company will improve Johnson & Johnson’s portfolio of drugs to treat rare diseases.

  • 01/26/2017 01:38:57

    Johnson & Johnson to buy Actelion for $30 billion, spin off R&D unit

    ZURICH (Reuters) - U.S. healthcare giant Johnson & Johnson will acquire Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, the companies said on Thursday.

  • 01/24/2017 10:22:00

    Johnson & Johnson Opens 2017 on a Cautious Note

    The healthcare conglomerate forecast lower revenue and earnings growth than investors had hoped.

  • 01/06/2017 00:01:42

    J&J, Actelion approach Swiss takeover board over deal structure: paper

    ZURICH (Reuters) - Johnson & Johnson and Actelion have asked Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm, newspaper Tages-Anzeiger reported on Friday, without saying how it got the information.

  • 12/29/2016 09:00:34

    Exclusive: J&J discussing breaking up Actelion in an acquisition - sources

    (Reuters) - Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd that would separate its commercialized portfolio from its research and development (R&D) assets, people familiar with the matter said on Thursday.

  • 12/13/2016 21:16:38

    Actelion says it continues deal talks as J&J drops out

    (Reuters) - Switzerland's Actelion Ltd said on Tuesday that it was in talks with an undisclosed suitor about a "strategic transaction," even as another potential acquirer, U.S. healthcare company Johnson & Johnson , ended talks.

  • 12/12/2016 14:03:47

    Dow logs 6th consecutive record close

    The Dow Jones Industrial Average notched its sixth consecutive record close on Monday, even as the other main stock-market benchmarks finished lower. The blue-chip gauge [s:djia] gained 39.37 points, or 0.2%, to 19,796.22, led by Johnson & Johnson and Pfizer Inc. . Meanwhile, the S&P 500 index shed 2.57 points, or 0.1%, to 2,256.96 as a selloff in financials and consumer discretionary shares offset gains by telecommunications and utilities firms. The Nasdaq Composite Index slid 31.96 points, or 0.6%, to 5,412.54. Both the S&P and Nasdaq snapped six-session winning streaks. Surging oil prices helped support energy shares. U.S.-traded crude oil futures settled at their highest levels since July 2015.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/11/2016 14:55:32

    Johnson & Johnson shares could rally about 20 percent: Barron's

    Johnson & Johnson(JNJ) shares could rally about 20 percent to the mid-$130s as operating improvements spur earnings growth, Barron's said in a report. Healthcare stocks have taken a hit since U.S. President-elect Donald Trump vowed to bring down drug prices.

  • 12/01/2016 17:48:31

    Johnson & Johnson Must Pay 6 Implant Patients $1 Billion

    A federal jury found that metal-on-metal Pinnacle hip implants were defectively designed, and that the company did not warn consumers of the risks.

  • 12/01/2016 17:37:27

    Johnson & Johnson hit with over $1 billion verdict on hip implants

    (Reuters) - A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants.

  • 11/25/2016 17:03:38

    Johnson & Johnson approaches Actelion about takeover deal

    U.S. healthcare company Johnson & Johnson (JNJ) said on Friday it was in preliminary talks with Actelion about a potential takeover of Europe's largest biotech firm, currently valued at about $20 billion. Lung disease specialist Actelion confirmed it had been approached and said there was no certainty a deal would occur.

  • 11/25/2016 10:10:05

    Actelion confirms Johnson & Johnson approach

    Actelion has confirmed it has been approached by Johnson & Johnson about a possible transaction to take over the Swiss drugmaker.

  • 11/25/2016 05:35:26

    Swiss drug company Actelion shares surge on report of possible Johnson & Johnson bid

    Shares of Swiss drug company Actelion Ltd. surged 14% Friday, after a report that Johnson & Johson has approached the company with a view to a takeover. Bloomberg News said talks are at an early stage. The Swiss company has a market capitalization of about $17 billion. It has brought new lung treatments to market that are expected to reduce its reliance on its Tracleer drug, which is used to treat high bloody pressure that affects arteries in the lungs, according to Bloomberg. Johnson & Johnson shares were not active premarket, but are up 10% in the year so far, while the Dow Jones Industrial Average has gained 9.5%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/25/2016 00:48:28

    J&J makes takeover approach for Swiss drugmaker Actelion: Bloomberg

    - U.S. healthcare company Johnson & Johnson (JNJ) has approached Swiss biotechnology firm Actelion Ltd about a potential takeover, Bloomberg reported on Thursday, citing people it said were familiar with the matter. The report said deliberations were still at an early stage following Johnson & Johnson's (JNJ) initial offer, and Actelion was working with an adviser to explore options.

  • More trends:

    Johnson ControlsJCI+4.65% | Jones EnergyJONE+6.23% | Jones Lang LaSalle IncorporatedJLL | Journal Media GroupJMG | Joy Global Inc.JOY | JP Energy Partners LPJPEP | JPMorgan China Region FundJFC | Jumei International Holding LimitedJMEI | Juniper NetworksJNPR | Jupai Holdings LimitedJP |